Charting New Frontiers in GvHD Treatment: Insights from Niktimvo™ FDA approval
September 4, 2024
On August 14, 2024, Syndax and Incyte announced the FDA approval of Niktimvo™ (axatilimab-csfr), a CSF-1R monoclonal antibody, for the treatment of chronic graft-versus-host disease (GvHD). Axatilimab is the first CSF-1R monoclonal antibody to receive approval, specifically targeting the drivers of inflammation and fibrosis in chronic GvHD (Business Wire, 2024). CSF-1R, a cell surface protein, […]
